Section 3 Drug Trial for ALS Halted for Lack of Efficacy

Section 3 Drug Trial for ALS Halted for Lack of Efficacy

A global part 3 trial of ravulizumab (Ultomiris) for adults with amyotrophic lateral sclerosis (ALS) is being discontinued following an recordsdata overview, its producer has launched. The CHAMPION-ALS placebo-managed trial had enrolled 382 adults with sporadic or familial ALS at…